48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2021-04, Vol.16 (4), p.S720-S721
Main Authors: Paz-Ares, L., Owonikoko, T.K., Johnson, M., Govindan, R., Izumi, H., Lai, V., Borghaei, H., Boyer, M., Boosman, R.J., Hummel, H-D., Blackhall, F., Dowlati, A., Zhang, Y., Mukherjee, S., Sable, B., Pati, A., Shetty, A., Sadraei, N. Hashemi, Champiat, S.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1556-0864
1556-1380
DOI:10.1016/S1556-0864(21)01890-6